Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Sees Neurontin Exclusivity Through 2002, Pregabalin Filing By Year-End

Executive Summary

Pfizer expects at least 30 months of additional exclusivity for the epilepsy agent Neurontin (gabapentin) beyond the expiration of the basic compound patent July 15.
Advertisement

Related Content

Alpharma Generic Neurontin Approval Precedes FDA Reinspection
Neurontin Bulk Supply May Limit Generic Uptake, Pfizer Says
Generic Neurontin: Hurdles To TorPharm Approval Expected To Clear In Jan.
Bear Stearns Healthcare Conference In Brief
Neurontin Patent Defense Takes Center Stage In Senate Hearing
Par Responds To Process Patents: FineTech Acquisition Valued At $109 Mil.
Pfizer Pregabalin NDA Will Include Anxiety Use; Filing Date Pushed To 2002
Pfizer Neurontin Neuropathic Pain NDA Planned; Relpax Awaits New Study
Bristol Taxol Exclusivity Continues, Thanks To ABI Cremophor-Free Patent
Lipitor Holds Up In Merger Dispute; Warner-Lambert, Pfizer Beat Expectations
Advertisement
UsernamePublicRestriction

Register

PS036432

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel